Skip to main content
Download PDF

Late-onset cblC defect: clinical, biochemical and molecular analysis

Orphanet Journal of Rare Diseases volume 18, Article number: 306 (2023) Cite this article

Abstract

Background

cblC defect is the most common type of methylmalonic acidemia in China. Patients with late-onset form (>1 year) are often misdiagnosed due to heterogeneous symptoms. This study aimed to describe clinical characteristics and evaluate long-term outcomes of Chinese patients with late-onset cblC defect.

Methods

A total of 85 patients with late-onset cblC defect were enrolled. Clinical data, including manifestations, metabolites, molecular diagnosis, treatment and outcome, were summarized and analyzed.

Results

The age of onset ranged from 2 to 32.8 years old (median age 8.6 years, mean age 9.4 years). The time between first symptoms and diagnosis ranged from a few days to 20 years (median time 2 months, mean time 20.7 months). Neuropsychiatric symptoms were presented as first symptoms in 68.2% of cases, which were observed frequently in schoolchildren or adolescents. Renal involvement and cardiovascular disease were observed in 20% and 8.2% of cases, respectively, which occurred with the highest prevalence in preschool children. Besides the initial symptoms, the disease progressed in most patients and cognitive decline became the most frequent symptom overall. The levels of propionylcarnitine, propionylcarnitine / acetylcarnitine ratio, methylmalonic acid, methylcitric acid and homocysteine, were decreased remarkably after treatment (P<0.001). Twenty-four different mutations of MMACHC were identified in 78 patients, two of which were novel. The c.482G>A variant was the most frequent mutated allele in this cohort (25%). Except for 16 patients who recovered completely, the remaining patients were still left with varying degrees of sequelae in a long-term follow-up. The available data from 76 cases were analyzed by univariate analysis and multivariate logistic regression analysis, and the results showed that the time from onset to diagnosis (OR = 1.025, P = 0. 024) was independent risk factors for poor outcomes.

Conclusions

The diagnosis of late-onset cblC defect is often delayed due to poor awareness of its various and nonspecific symptoms, thus having an adverse effect on the prognosis. It should be considered in patients with unexplained neuropsychiatric and other conditions such as renal involvement, cardiovascular diseases or even multiple organ damage. The c.482G>A variant shows the highest frequency in these patients. Prompt treatment appears to be beneficial.

Introduction

Cobalamin C defect (cblC, OMIM 277,400), accounting for 70% of cases with methylmalonic acidemia (MMA), is the most common disorder of organic acid metabolism in China. This disorder is caused by mutations in the MMACHC gene, leading to the impaired conversion of cobalamin into its two metabolically active forms, adenosylcobalamin and methylcobalamin. They are essential cofactors for the conversion of homocysteine (HCY) into methionine in the cytosol and methylmalonyl-CoA into succinyl-CoA in mitochondria, respectively. Their deficiency results in the accumulation of HCY and methylmalonic acid accompanied by normal or decreased methionine levels [1, 2]. According to a recent systematic literature review, the detection rate of MMA (all types) was 1/126,582, 1/89,286, 1/81,967, and 1/16,556 in Asia-Pacific, Europe, North America and the Middle East and North Africa (MENA) regions, respectively [3]. The incidence of MMA in China varies from region to region, which was reported to be 1/5589 in Shandong Jining district [4], 1/6032 in Henan province [5], 1/16,833 in Jiangsu Xuzhou district [6], 1/38,667 in Shanghai [7]and 1/46,531 in Zhejiang province [8].

The cblC defect is inherited in an autosomal recessive pattern. The age of onset ranges from the prenatal to adult stage and clinical presentation can vary considerably, ranging from a mild, potentially asymptomatic phenotype to an acute or chronic form with disease progression, which is at risk of disability or even life-threatening [9,10,11,12]. Based on the age of onset, it can be classified into two distinct phenotypes: early onset and late onset [2]. Patients with early onset, presenting symptoms in the first year of life, show severe clinical manifestations, such as feeding difficulties, growth retardation, lethargy, hypotonia, neurological, ophthalmological and hematological complications. Patients with late onset can present symptoms at any time after one year of age and they can be easily misdiagnosed or missed due to the heterogeneous clinical manifestations, encompassing neurological, psychiatric, renal and thromboembolic symptoms [13,14,15]. Early diagnosis and prompt treatment may prevent symptoms or ameliorate the disease course [16].

In the present study, we performed a detailed retrospective chart review of clinical data in 85 patients with late-onset cblC defect. The aim of this research was to investigate the clinical, biochemical and molecular characteristics of late- onset cblC defect and evaluate their long-term outcomes.

Methods

Patients

A total of 85 patients with late-onset cblC defect were recruited at our center between 2010 and 2022. All patients were from unrelated families, except for five siblings P3 and P4, P9 and P23, P42 and P43, P79 and P80 as well as P82 and P83. Written informed consent was obtained from the parents or legal guardians of the study participants. This study was approved by the Ethics Committee of Xinhua Hospital (approval No. XHEC-D-2023-058).

Metabolite detection

Blood levels of acylcarnitines, including propionylcarnitine (C3) and acetylcarnitine (C2) as well as amino acids were detected by tandem mass spectrometry (MS/MS; Applied Biosystems, API 4000, California, United State) on dried blood filter papers. The ratios of C3/C2 were calculated at the same time. Urinary organic acids including methylmalonic acid and methylcitric acid (MCA) were measured by gas chromatography-mass spectrometry (GC/MS; Shimadzu Limited, QP2010, Kyoto, Japan). Blood HCY were measured by fluorescence polarization immunoassay.

Mutation analysis

Genomic DNA was extracted from peripheral blood samples. Gene test was performed by Sanger or next generation sequencing. Reference sequences MMACHC (NM_015506.2) were obtained from NCBI GENEBANK to identify mutations. The ClinVar database, the HGMD database, and the previous literatures were used to identify whether the mutations had been reported. The pathogenicity of novel variants was evaluated based on the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. The potential pathogenicity of mutations was predicted by Mutation Taster, PolyPhen-2, Provean and SIFT software.

Treatment

Personalized treatment strategies were given to patients with late-onset cblC defect as soon as it was diagnosed. Intramuscular hydroxyl cobalamin administration was the primary treatment, at a dose of 10 mg/day. In addition, oral administration of L-carnitine (50–100 mg/kg/day), betaine (50–100 mg/kg/day) and folic acid (5–10 mg/day) were also prescribed. The long-term treatment was adjusted depending on the condition of individual patients [16, 17]. Symptomatic treatment was performed for patients with renal disease, cardiovascular disease and other complications.

Follow-up and outcome evaluation

Patients were followed up every 3–6 months after diagnosis. The content included recent treatment strategies, condition changes, growth and development. Amino acids, acylcarnitines and HCY levels in blood and organic acids levels in urine were analyzed regularly. Blood routine examination, liver function and brain magnetic resonance imaging (MRI) were also monitored. According to the basic motor function and language development evaluation method mentioned in the literature [18], patients were divided into two main groups: normal outcome group and poor outcome group. The normal group outcome showed no significant impairments in daily functioning, whereas the poor outcome group presented with deficits, such chronic renal failure and progressive pulmonary arterial hypertension (PAH) and/or delayed attainment of motor and/or speech milestones, such as requiring assistance for walk and being unable to effectively communicate.

Statistical analyses

Statistical analyses were performed using SPSS 26.0 (IBM Corp., Armonk, New York). Continuous variables are presented as the mean ± SD or median (range). Data that did not significantly deviate from normal distribution were tested using an unpaired two-tailed t-test, and non-normally distributed data were tested using the Mann-Whitney U test. Categorical variables are presented as frequencies and percentages. Chi-squared test or Fisher’s precision probability test were used to compared categorical variables. Multivariate logistic regression analysis was performed using variables with significant differences in univariate analysis. Statistical significance was established at P<0.05.

Results

Clinical characteristics

Detailed patient information is summarized in Supplementary Table S1. In this cohort, 85 patients with late-onset cblC defect were recruited, including 51 males and 34 females. All patients were diagnosed due to disease onset with symptoms. The age of onset ranged from 2 to 32.8 years old (median age 8.6 years, mean age 9.4 years). The time between first symptoms and diagnosis ranged from a few days to 20 years (median time 2 months, mean time 20.7 months). Most patients (58/85, 68.2%) had neuropsychiatric symptoms as first presenting symptoms, followed by renal involvement (17/85, 20.0%), cardiovascular disease (7/85, 8.2%) and metabolic crises (3/85, 3.5%). Detailed age specific patterns of initial symptoms are further depicted in Fig. 1. PAH (median age at onset 4.3, range 3–12 years), proteinuria/hematuria (median age at onset 4.5, range 2.5-8 years) and glomerulopathies (median age at onset 4.5, range 1-6.6 years) were the most frequent symptoms in preschool children. While, in schoolchildren or adolescents, convulsion (median age at onset 6.5, range 2.3–14.8 years), vomiting (median age at onset 7, range 2.5–16 years), lethargy/coma (median age at onset 9.8, range 3.3–19.5 years), cognitive decline (median age at onset 11.6, range 8.6–19 years), gait instability/ataxia (median age at onset 12.5, range 3.3–15.5 years), lower limbs weakness (median age at onset 14, range 3-19.5 years) and psychiatric symptoms (median age at onset 16, range 2.0-32.8 years) were dominant features. And median time from neuropsychiatric symptoms, renal involvement, cardiovascular disease and metabolic crises onset to diagnosis was 2.5 months (mean 15.8, range 0.2–240), 2 months (mean 37.8, range 0.2–149), 4 months (mean 5, range 0.2-146.8) and 1 months (mean 1.7, range 0.5–3.7), respectively.

Fig. 1
figure 1

Age at onset for main initial symptoms in 85 patients with the late-onset cblC defect

Full size image

Besides the first symptoms at onset, disease progressed in overwhelming majority of patients with cblC defect. Figure 2 shows the frequency of overall clinical symptoms in 85 patients with late-onset cblC defect. Overall, neuropsychiatric symptoms were the most common clinical symptoms among our patients, which were present in 80.0% of cases (68 patients). Among them, cognitive decline, manifesting as a decline in school and work performance or sluggish response, was the most frequent clinical manifestation and presented in 58.8% of cases (50 patients) during disease progression. Other neuropsychiatric symptoms, such as motor involvement (encompassing gait instability, ataxia, lower limbs weakness and spastic paraplegia), seizures/convulsion, psychiatric symptoms (encompassing social withdrawal, insomnia, euphoria anxiety, depression and auditory hallucination), lethargy/coma, speech and language impairment, incontinence and visual involvement were present in 57.6% (49 patients), 28.2% (24 patients), 23.5% (20 patients), 22.4% (19 patients),12.9% (11 patients), 7.1% (6 patients) and 5.9% (5 patients) of cases, respectively. Renal involvement was observed in 23.5% (20 patients) of cases, ranging from proteinuria or hematuria (16.5%), glomerular diseases (5.9%), kidney failure (5.9%) and hemolytic uremic syndrome (HUS, 2.4%). Cardiovascular disease, such as PAH (5.9%), heart failure (4.7%) and cardiomyopathy (2.4%), were identified in eight patients. Further, eight patients (9.4%) presented with anemia, three patients (3.5%) had anorexia and three patients (3.5%) showed signs of metabolic crises, such as vomiting, dyspnea and anorexia.

Fig. 2
figure 2

Frequency of overall clinical symptoms in 85 patients with late-onset cblC-type MMA

Full size image

Brain MRI findings were available for 27 patients. Among them, normal brain imaging was present in four patients (14.8%). The most common abnormalities of brain MRI findings were cortical atrophy (10/27, 37.0%), ventricular dilation or sulcal widening (7/27, 25.9%) and periventricular white matter change (4/27, 14.8%). The other findings of brain MRI included hydrocephalus, subacute cerebral infarction, encephalomalacia foci, cerebral venous sinus thrombosis and thinning of the corpus callosum, which was present in single patient.

Long-term treatment

During the follow-up, all patients followed a normal diet. According to the literature and our clinical experience, a satisfactory metabolic control is obtained in the case that HCY is not exceeding 50 µmol/L [19]. Thus, hydroxyl cobalamin dosages were adjusted depending on the condition of individual patients, with the single doseof 5 to 20 mg each time, once a day to once every three weeks. Up to February 2023, two patients (P47 and P72) were lost of follow-up. 13 patients were only treated with intramuscular hydroxyl cobalamin, discontinuing oral administration. Two patients (P1 and P29) had complete withdrawal voluntarily because of the improvement of symptoms, which occurred 5 and 2 years after treatment, respectively. The remaining 68 patients accepted treatments with intramuscular hydroxyl cobalamin combined with oral drugs, including betaine, L-carnitine and/or folic acid. Further, symptomatic treatment was performed for patients with some complications such as renal and cardiovascular diseases.

Biochemical characteristics

As the biochemical makers of patients with cblC defect, blood values C3, C3/C2 ratio, HCY and urinary methylmalonic acid and MCA were measured before and after treatment. Since there were some confirmed patients who had begun vitamin B12 treatment in other hospitals and then transferred to our clinic, their biochemical results were partly missing. Therefore, we just analyzed specific biochemical results before and after treatment. As is shown in Table 1, the levels of HCY and methylmalonic acid were elevated before treatment, accompanied by increased or normal C3, C3/C2 ratio and MCA. In addition, all the biochemical markers above revealed statistically significant before and after treatment (P<0.001). These data indicated that patients were vitamin B12 responsive.

Table 1 Comparison of biochemical data of patients with late-onset cblCdefect in blood and urine before and after treatment
Full size table

Mutation spectrum

Molecular analysis was performed on 78 patients. The mutation spectrum of MMACHC gene observed in this study is shown in Supplementary Table S1. Five cases (P9, P11, P23, P66 and P75) harbored homozygous variants (two with c.80 A>G, two with c.394 C>T and one with c.482G > A mutation homozygote) and the remaining 73 cases harbored compound heterozygous variants. A total of 24 different variants are associated with late-onset cblC defect in our cohort (Fig. 3). They were distributed throughout MMACHC gene from exon 1 to exon 4. The c.482G>A occurred with the highest frequency, followed by c.609G > A, c.80 A > G and c.394 C > T, accounting for 25%, 19.9%,13.5% and 6.4% of all alleles, respectively. Among them, a total of two novel mutations have never been reported before, including c.396dupT and c.565 C>G, which were predicted as disease-causing by Mutation Taster, PolyPhen-2, Provean and SIFT software.

Fig. 3
figure 3

Distribution of the mutations in the MMACHC gene in 78 patients with late-onset cblC defect

Novel mutations are shown in red.

Full size image

Clinical outcomes

Up to February 2023, the patients were 4.6–37.2 years old, with a median age of 15 and the median time of follow-up was 4.9 years (mean time 5.1 years, range 0.5-13.4years). Two patients (2.4%) were lost to follow-up (P47 and P72) and the remaining patients were alive.16 patients (18.8%) were healthy. Clinical symptoms improved but not completely recovered in 14 patients (16.5%), with five patients suffering from cardiovascular disease, eight patients manifesting renal involvement and one patient subject to anemia. The remaining 53 patients (62.4%) suffered from poor outcomes, such as movement disorders, recurrent convulsion, intellectual impairment, chronic renal failure and progressive PAH. (Supplementary Table S1)

Univariate analysis and multivariate logistic regression analysis were performed among 76 patients to determine the factors affecting prognosis after excluding patients who were lost follow-up and with missing data. Factors including age at onset, time from onset to diagnosis, initial symptoms and genotype were analyzed. Considering that c.482G > A, c.80 A>G and c.394 C>T were observed frequently in late-onset cases according to our findings and literature [20, 21], the genotype was divided into four groups, c.482G > A, c.80 A>G, c.394 C>T and others. As shown in Table 2, there were significant differences in age at onset, time from onset to diagnosis, neuropsychiatric symptoms or renal involvement as initial symptoms and carrying c.482G>A or c.80 A>G variant between normal outcome groups and poor outcome groups. Multivariate logistic regression analysis was performed using above variables to determine the independent risk factors. The results are listed in Table 3. It showed that the time from onset to diagnosis (OR = 1.025, P = 0. 024) was independent risk factors for poor outcomes.

Table 2 Comparison of baseline characteristics between patients with normal and poor outcomes
Full size table
Table 3 Results of logistic regression analysis of factors influencing prognosis of patients with late-onset cblC defect
Full size table

Discussion

Approximately 90% of reported patients with cblC defect are severe infantile early onset [9]. While clinical manifestations of late-onset form are quite different from early-onset cases and often complicated with multiple organ damage, thus these patients might be easily misdiagnosed or missed [13, 15, 22]. In the present study, we collected clinical data from 85 patients with late-onset cblC defect, described their clinical, biochemical and molecular characteristics and analyzed prognosis and influencing factors.

In our study, 85 patients were healthy before onset, exhibiting normal development. The initial symptoms varied widely and patterns of these clinical manifestations seem to vary with age. Among them, neuropsychiatric symptoms were the most common manifestations in schoolchildren or adolescents. Renal involvement and cardiovascular disease showed a high prevalence in preschool children and were not observed in adults. Metabolic crises were relatively rare. In agreement with this finding, Huemer et al [15] also found that, HUS and PAH were main presenting symptoms in preschool children. While psychiatric symptoms, cognitive decline, ataxia and myelopathy were frequent in older children or adolescents. And in adults, thrombosis, neuropathy, myelopathy and glomerulopathies were mainly observed. Besides initial symptoms, disease progressed in most patients. Overall, cognitive decline and motor involvement were dominant symptoms, while ocular involvement seems to be rare in late-onset cblC defect. All these findings were correlated with previous studies [13, 22]. This suggests that patients with late-onset cblC defect can present with a wide spectrum of nonspecific symptoms, of which neuropsychiatric symptoms are the most common manifestations and often occur as the initial symptoms. The time between first symptoms and diagnosis ranged widely in our study, the longest of which was up to 20 years. Therefore, late-onset cblC defect is a disease involving multiple systems and organs, and it should be considered when patients have unexplained neuropsychological symptoms, metabolic crises or other organ involvement. And detailed statistical analysis of larger groups of patients may assist in further exploring the relationship with genotypes for other symptoms and the correlation between time from onset to diagnosis and initial symptoms. Despite heterogeneous presenting symptoms, heterogeneous symptoms, metabolite measurement using MS/MS and GC/MS is considered as a necessary method for the diagnosis of MMA. In this study, plasma HCY and urinary methylmalonic acid concentrations in all patients were markedly increasing, which are regarded as useful indicators for the prompt diagnosis of cblC defect [16].

Abnormal brain MRI results also contribute to evaluating the extent of brain injury and prognosis. In our study, cerebral atrophy, periventricular white matter abnormality, ventricular dilation and sulcal widening were the main findings in patients with cblC defect, which was correlated with previously published literature [23, 24]. However, MRI features of MMA are nonspecific and do not permit differentiation from other metabolic diseases and classification of MMA.

The pathogenic mechanisms have not been entirely elucidated at present. One of the probable reasons might be associated with mitochondrial energy metabolism disorders, which are caused by the accumulation of toxic metabolites [2]. The variety of clinical manifestations in patients with combined MMA seem to be more substantial, which may result from high levels of HCY and low concentrations of methionine. It seems to be believed that the synergistic effect of different mechanisms might be responsible for multiple systems and organs involvement, such as direct neurotoxicity causing cell death, oxidant stress and inflammation, the initiation of a cellular cascade of apoptosis, interference with DNA repair system and N-methyl-d-aspartate-mediated mechanisms [25, 26].

Until now, more than 100 different mutations of MMACHC have been reported, and c.482G > A, c.80 A>G and c.394 C>T were observed frequently in late-onset cases [20, 21]. From a genetic point of view, late-onset cases tend to be characterized by compound heterozygosity with a milder variant (missense, inframe deletion/ duplication), which seems to retain a residual function. In our study, 93.6% (73/78) of cases harbored compound heterozygous variants. A total of 24 different mutations of MMACHC were identified, of which c.396dupT and c.565 C>T were novel variants. Consistent with previous studies, c.482G > A, c.80 A>G and c.394 C>T were observed frequently in our cohort of late-onset cases, ranking first, third and fourth most common alleles, respectively. The c.609G > A variant also occurred frequently in our study. This nonsense mutation results in a pre-mature termination codon, which is predicted to cause a truncated or absent MMACHC protein, thus it is highly prone to the early-onset form [27, 28]. It is notable that all patients with c.609G > A were compound heterozygotes for a missense variant or c.394 C>T variant, except one with a deletion mutation in the MMACHC gene. It has been reported that the early-onset allele tends to be underexpressed when compared to the late-onset allele [20]. Therefore, one of the possible reasons might be associated with the lower expression of MMACHC transcription in the c.609G > A variant. In addition, c.609G > A was reported to be the most common variant among Chinese population [12]. As a result, its high frequency in late-onset cases might be explained.

At present, the mainstay of therapy for cblC disease is intramuscular hydroxyl cobalamin, supplemented with oral drugs including betaine, L-carnitine and/or folic acid [17, 29]. Most patients in our study were treated with the above therapy. Although there are theoretical reasons for using L-carnitine and folinic acid, no beneficial effect of adjunctive therapy with folic folinic acid and L-carnitine has been reported in some cases [30, 31]. In 13 patients who only received treatment with hydroxyl cobalamin in the present study, 10 had a c.482G > A variant, and all of their clinical symptoms as well as biochemical data were stable during follow-up. Further data need to determine the effect of only hydroxyl cobalamin administration.

Although late-onset cases are less life-threatening compared to early-onset cases, lack of diagnosis or even late initiation of treatment can lead to a less favorable course with significant morbidity or even death [32]. In this study, all patients who had follow-up survived, of whom 30 patients with normal outcomes, showed no significant impairments in daily functioning, while 53 patients suffered from poor outcomes during the follow-up. This suggests that late-onset cblC defect seems to have a high disability rate. The results of multivariate logistic regression analysis indicated that time from onset to diagnosis is the independent risk factor affecting prognosis. Thus, early diagnosis and timely treatment is essential for prognosis improvement. Luckily, MMA has been included in expanded newborn screening in several countries and cost-effectiveness of using MS/MS in NBS have been reported [33, 34]. However, false positive and negative results should be considered [35,36,37]. Mutation analysis is essential for a definite diagnosis. Thus, combined biochemical and mutation analysis is recommended to achieve an early and precise diagnosis.

Conclusion

In conclusion, late-onset cblC defect is difficult to identify due to a wide diversity of symptoms, of which various neuropsychiatric symptoms are the most common symptoms. This disease should be considered in unexplained cases, especially in patients with neuropsychiatric, renal and cardiovascular diseases or even multiple organ damage. The c.482G > A variant is the most frequent variant in late-onset cases. Raising awareness for this disorder helps to improve outcome, accompanied by prompt treatment.

Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Abbreviations

cblC:

cobalamin C

MMA:

Methylmalonic acidemia

HCY:

Homocysteine

MENA:

Middle East and North Africa

C3:

propionylcarnitine

C2:

Acetylcarnitine

C3/C2:

propionylcarnitine to acetylcarnitine ratio. GC/MS:Chromatography/mass spectrometry

MS/MS:

Tandem mass spectrometry

MCA:

Methylcitric acid

ACMG:

American College of Medical Genetics and Genomics

MRI:

Magnetic resonance imaging

HUS:

Hemolytic uremic syndrome

PAH:

Pulmonary arterial hypertension

References

  1. Lerner-Ellis JP, Tirone JC, Pawelek PD, Doré C, Atkinson JL, Watkins D, Morel CF, Fujiwara TM, Moras E, Hosack AR, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet. 2006;38(1):93–100.

    Article  CAS  PubMed  Google Scholar 

  2. Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis. 2011;34(1):127–35.

    Article  CAS  PubMed  Google Scholar 

  3. Almási T, Guey LT, Lukacs C, Csetneki K, Vokó Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency. Orphanet J Rare Dis. 2019;14(1):84.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Yang C, Zhou C, Xu P, Jin X, Liu W, Wang W, Huang C, Jiang M, Chen X. Newborn screening and diagnosis of inborn errors of metabolism: a 5-year study in an eastern chinese population. Clin Chim Acta. 2020;502:133–8.

    Article  CAS  PubMed  Google Scholar 

  5. Zhao DL, Li XL, Ni M, Jia CL, Zhang J. Screening results of neonatal methylmalonic acidemia (MMA) of 349858 cases in Henan province. Chin J Birth Health Heredity. 2016;0(8):86–790.

    Google Scholar 

  6. Zhou W, Li H, Wang C, Wang X, Gu M. Newborn screening for Methylmalonic Acidemia in a Chinese Population: Molecular Genetic confirmation and genotype phenotype correlations. Front Genet. 2018;9:726.

    Article  CAS  PubMed  Google Scholar 

  7. Gu X, Wang Z, Ye J, Han L, Qiu W. Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening. Ann Acad Med Singap. 2008;37(12 Suppl):107–104.

    PubMed  Google Scholar 

  8. Hong F, Huang X, Zhang Y, Yang J, Tong F, Mao H, Huang X, Zhou X, Yang R, Zhao Z. [Screening for newborn organic aciduria in Zhejiang province:prevalence, outcome and follow-up]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2017;46(3):240–7.

    PubMed  PubMed Central  Google Scholar 

  9. Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen D, Boneh A, Burlina AB, Cerone R, Garcia P, Gökçay G, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis. 2014;37(5):831–40.

    Article  CAS  PubMed  Google Scholar 

  10. Carrillo-Carrasco N, Chandler RJ, Venditti CP. Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis. 2012;35(1):91–102.

    Article  CAS  PubMed  Google Scholar 

  11. Liu Y, Liu YP, Zhang Y, Song JQ, Zheng H, Dong H, Ma YY, Wu TF, Wang Q, Li XY, et al. [Heterogeneous phenotypes, genotypes, treatment and prevention of 1 003 patients with methylmalonic acidemia in the mainland of China]. Zhonghua Er Ke Za Zhi. 2018;56(6):414–20.

    CAS  PubMed  Google Scholar 

  12. Wang F, Han L, Yang Y, Gu X, Ye J, Qiu W, Zhang H, Zhang Y, Gao X, Wang Y. Clinical, biochemical, and molecular analysis of combined methylmalonic acidemia and hyperhomocysteinemia (cblC type) in China. J Inherit Metab Dis. 2010;33(Suppl 3):435–42.

    Article  Google Scholar 

  13. Kalantari S, Brezzi B, Bracciamà V, Barreca A, Nozza P, Vaisitti T, Amoroso A, Deaglio S, Manganaro M, Porta F, et al. Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists. Orphanet J Rare Dis. 2022;17(1):33.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Huemer M, Baumgartner MR. The clinical presentation of cobalamin-related disorders: from acquired deficiencies to inborn errors of absorption and intracellular pathways. J Inherit Metab Dis. 2019;42(4):686–705.

    Article  CAS  PubMed  Google Scholar 

  15. Huemer M, Scholl-Bürgi S, Hadaya K, Kern I, Beer R, Seppi K, Fowler B, Baumgartner MR, Karall D. Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis. 2014;9:161.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, Burlina A, Cerone R, Couce ML, Garcia-Cazorla A, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21–48.

    Article  CAS  PubMed  Google Scholar 

  17. Forny P, Hörster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, Dixon M, Grünert SC, Grunewald S, Haliloglu G, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44(3):566–92.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Liang EH, Zhang L, Qiu H, Ye W, Xu J, Gong F, Gu Z, Han X. Evaluation of the clinical, biochemical, neurological, and genetic presentations of glutaric aciduria type 1 in patients from China. Front Genet. 2021;12:702374.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Dionisi-Vici C, Martinelli D, Ceravolo F, Boenzi S, Pastore A. Optimizing the dose of hydroxocobalamin in cobalamin C (cblC) defect. Mol Genet Metab. 2013;109(4):329–30.

    Article  CAS  PubMed  Google Scholar 

  20. Lerner-Ellis JP, Anastasio N, Liu J, Coelho D, Suormala T, Stucki M, Loewy AD, Gurd S, Grundberg E, Morel CF, et al. Spectrum of mutations in MMACHC, allelic expression, and evidence for genotype-phenotype correlations. Hum Mutat. 2009;30(7):1072–81.

    Article  CAS  PubMed  Google Scholar 

  21. Almannai M, Marom R, Divin K, Scaglia F, Sutton VR, Craigen WJ, Lee B, Burrage LC, Graham BH. Milder clinical and biochemical phenotypes associated with the c.482G > A (p.Arg161Gln) pathogenic variant in cobalamin C disease: implications for management and screening. Mol Genet Metab. 2017;122(1–2):60–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chen Z, Dong H, Liu Y, He R, Song J, Jin Y, Li M, Liu Y, Liu X, Yan H, et al. Late-onset cblC deficiency around puberty: a retrospective study of the clinical characteristics, diagnosis, and treatment. Orphanet J Rare Dis. 2022;17(1):330.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Radmanesh A, Zaman T, Ghanaati H, Molaei S, Robertson RL, Zamani AA. Methylmalonic acidemia: brain imaging findings in 52 children and a review of the literature. Pediatr Radiol. 2008;38(10):1054–61.

    Article  PubMed  Google Scholar 

  24. Weisfeld-Adams JD, Bender HA, Miley-Åkerstedt A, Frempong T, Schrager NL, Patel K, Naidich TP, Stein V, Spat J, Towns S, et al. Neurologic and neurodevelopmental phenotypes in young children with early-treated combined methylmalonic acidemia and homocystinuria, cobalamin C type. Mol Genet Metab. 2013;110(3):241–7.

    Article  CAS  PubMed  Google Scholar 

  25. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. BioFactors. 2009;35(2):120–9.

    Article  CAS  PubMed  Google Scholar 

  26. Roehrs C, Garrido-Sanabria ER, Da Silva AC, Faria LC, Sinhorin VD, Marques RH, Priel MR, Rubin MA, Cavalheiro EA, Mello CF. Succinate increases neuronal post-synaptic excitatory potentials in vitro and induces convulsive behavior through N-methyl-d-aspartate-mediated mechanisms. Neuroscience. 2004;125(4):965–71.

    Article  CAS  PubMed  Google Scholar 

  27. He R, Mo R, Shen M, Kang L, Song J, Liu Y, Chen Z, Zhang H, Yao H, Liu Y, et al. Variable phenotypes and outcomes associated with the MMACHC c.609G > A homologous mutation: long term follow-up in a large cohort of cases. Orphanet J Rare Dis. 2020;15(1):200.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Wang C, Li D, Cai F, Zhang X, Xu X, Liu X, Zhang C, Wang D, Liu X, Lin S, et al. Mutation spectrum of MMACHC in chinese pediatric patients with cobalamin C disease: a case series and literature review. Eur J Med Genet. 2019;62(10):103713.

    Article  PubMed  Google Scholar 

  29. Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, Huemer M, Hochuli M, Assoun M, Ballhausen D, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Bartholomew DW, Batshaw ML, Allen RH, Roe CR, Rosenblatt D, Valle DL, Francomano CA. Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria. J Pediatr. 1988;112(1):32–9.

    Article  CAS  PubMed  Google Scholar 

  31. Ogier de Baulny H, Gérard M, Saudubray JM, Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr. 1998;157(Suppl 2):77–83.

    Article  Google Scholar 

  32. Powers JM, Rosenblatt DS, Schmidt RE, Cross AH, Black JT, Moser AB, Moser HW, Morgan DJ. Neurological and neuropathologic heterogeneity in two brothers with cobalamin C deficiency. Ann Neurol. 2001;49(3):396–400.

    Article  CAS  PubMed  Google Scholar 

  33. Hori D, Hasegawa Y, Kimura M, Yang Y, Verma IC, Yamaguchi S. Clinical onset and prognosis of asian children with organic acidemias, as detected by analysis of urinary organic acids using GC/MS, instead of mass screening. Brain Dev. 2005;27(1):39–45.

    Article  PubMed  Google Scholar 

  34. Heringer J, Valayannopoulos V, Lund AM, Wijburg FA, Freisinger P, Barić I, Baumgartner MR, Burgard P, Burlina AB, Chapman KA, et al. Impact of age at onset and newborn screening on outcome in organic acidurias. J Inherit Metab Dis. 2016;39(3):341–53.

    Article  PubMed  Google Scholar 

  35. Ryckman KK, Berberich SL, Shchelochkov OA, Cook DE, Murray JC. Clinical and environmental influences on metabolic biomarkers collected for newborn screening. Clin Biochem. 2013;46(1–2):133–8.

    Article  CAS  PubMed  Google Scholar 

  36. Peng G, Tang Y, Gandotra N, Enns GM, Cowan TM, Zhao H, Scharfe C. Ethnic variability in newborn metabolic screening markers associated with false-positive outcomes. J Inherit Metab Dis. 2020;43(5):934–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Estrella J, Wilcken B, Carpenter K, Bhattacharya K, Tchan M, Wiley V. Expanded newborn screening in New South Wales: missed cases. J Inherit Metab Dis. 2014;37(6):881–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge all patients and their family for participating in this study.

Funding

Scientific research Project Plan of Shanghai Municipal Health Commission (No.202140346).

Author information

Author notes

  1. Si Ding and Shiying Ling contributed equally to this work.

Authors and Affiliations

  1. Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute of Pediatric Research, Shanghai Jiao Tong University School of Medicine, 1665 KongJiang Road, Shanghai, 200092, China

    Si Ding, Shiying Ling, Lili Liang, Wenjuan Qiu, Huiwen Zhang, Ting Chen, Xia Zhan, Feng Xu, Xuefan Gu & Lianshu Han

Authors
  1. Si Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiying Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lili Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenjuan Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huiwen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ting Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xia Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Feng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xuefan Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lianshu Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SD contributed to reorganizing and analyzing the clinical data of the patients and drafting the manuscript. SL contributed to collecting and reorganizing the clinical data of the patients, and revising the manuscript. LL, WQ, HZ and XG contributed to collecting and treating the patients and providing the clinical data. TC, XZ and FX contributed to analyzing metabolites and gene variation. LH, as the doctor of most of the patients, contributed to designing the research, treating the patients, providing the clinical data and revising the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lianshu Han.

Ethics declarations

Informed consent

Written informed consent was obtained from all participants, and our study was approved by the Ethics Committee of Xinhua Hospital (Approval No. XHEC-D-2023-058).

Consent for publication

Participants provided written informed consent.

Conflict of interest

None declared.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ding, S., Ling, S., Liang, L. et al. Late-onset cblC defect: clinical, biochemical and molecular analysis. Orphanet J Rare Dis 18, 306 (2023). https://doi.org/10.1186/s13023-023-02890-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13023-023-02890-4

Keywords

Orphanet Journal of Rare Diseases

ISSN: 1750-1172